PTC Therapeutics (PTCT) Announces Earnings Results

Henrietta Strickland
March 8, 2018

(PTCT) in trading session dated January 05, 2018. PIXY shares have surged 52% as a result to trade at $3.94, but topped out right below the $4 mark - two times their annual low from December.

Now investors want to know the actual market worth of the company in the Stock Market. It has outperformed by 0.30% the S&P500. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since March 8, 2017 and is uptrending.

Many analysts are providing their Estimated Earnings analysis for PTC Therapeutics, Inc. and for the current quarter 6 analysts have projected that the stock could give an Average Earnings estimate of $-0.42/share. The Boys Arnold & Co Inc holds 38,535 shares with $5.59M value, down from 40,761 last quarter. Ptc Therapeutics Cmn (NASDAQ:PTCT)'s price sits 29.5% above from its 50-day moving average of $24.43 and 54.57% far from the stock's 200-day moving average which is $19.63. The stock decreased 0.91% or $0.04 during the last trading session, reaching $4.34. William Blair reaffirmed a "hold" rating on shares of PTC Therapeutics in a research report on Wednesday. It has outperformed by 87.81% the S&P500. (NASDAQ:PTCT). Schwab Charles Investment Management Inc invested in 0% or 178,795 shares. $12,675 worth of PTC Therapeutics, Inc. JP Morgan downgraded the stock to "Neutral" rating in Tuesday, February 23 report. During the same quarter a year ago, the company earned ($0.78) earnings per share. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the stock. Therefore 33% are positive. PTC Therapeutics has a 1-year low of $8.12 and a 1-year high of $28.75. RBC Capital Markets maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) on Wednesday, February 24 to "Neutral" rating. Ptc Therapeutics Cmn (NASDAQ:PTCT)'s price to free cash flow for trailing twelve months is 0. The firm earned "Buy" rating on Friday, November 11 by Citigroup. They set a "sector perform" rating for the company. New York-based Savings Bank Of Ny Mellon has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT) earned "Outperform" rating by Oppenheimer on Friday, October 16. The company presently has a consensus rating of "Hold" and a consensus price target of $21.86. The rating was maintained by BMO Capital Markets on Wednesday, February 28 with "Outperform". (NASDAQ:PTCT) has "Hold" rating given on Tuesday, September 26 by J.P. Morgan.

Investors sentiment decreased to 0.98 in 2017 Q3. The Russell 2000 index rose 4 points, or 0.3% to 1,566. (NASDAQ:PTCT) shares with value of $7,280 were sold by Utter Christine Marie. 25 funds opened positions while 45 raised stakes. Sectoral Asset Mngmt Inc holds 170,535 shares. JP Morgan downgraded PTC Therapeutics, Inc.

Trading volume is a gauge of how many times a stock is bought and sold in a given time period (most commonly, within a day of trading, known as the average daily trading volume - ADTV). Alliancebernstein LP holds 0% or 49,350 shares. The California-based Cove Street Capital Llc has invested 2.1% in the stock. 603.99 million shares or 0.25% more from 602.51 million shares in 2017Q2 were reported. Segantii Cap Management holds 64,000 shares. Tower Rech Cap Ltd Liability (Trc) holds 554 shares. Macquarie Group Limited reported 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Virginia Retirement Et Al holds 0% or 18,700 shares in its portfolio.

Since January 3, 2018, it had 0 insider purchases, and 4 insider sales for $61,523 activity. Swiss Retail Bank holds 0% of its portfolio in PTC Therapeutics, Inc.

In related news, CEO Stuart Walter Peltz sold 2,230 shares of the business's stock in a transaction dated Friday, January 5th. The hedge fund run by Jeffrey Jay held 460,000 shares of the health care company at the end of 2017Q3, valued at $9.21 million, up from 260,000 at the end of the previous reported quarter. The insider BABB RALPH W JR sold $5.78M. Wellington Management Grp Llp stated it has 1.15 million shares. Shares for $463,258 were sold by Burkhart Megan D. Another trade for 11,293 shares valued at $1.08M was made by Duprey David E on Saturday, January 27. The firm has a market capitalization of $1,110.00, a PE ratio of -9.29 and a beta of 1.71. The Business Bank segment offers various services and products, such as commercial loans and lines of credit, deposits, cash management, capital market products, worldwide trade finance, letters of credit, foreign exchange management, and loan syndication services to middle market businesses, multinational firms, and governmental entities.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on April, 26. The company's forward price to earnings ratio for next fiscal year is 0. The company reported the earnings of $0.03/Share in the last quarter where the estimated EPS by analysts was $-0.14/share.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by Click Lancashire

Discuss This Article